{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T18:35:30Z","timestamp":1788719730068,"version":"build-2803163510"},"reference-count":37,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chromosome 1 abnormalities (C1As) are common genetic aberrations among patients with multiple myeloma (MM). We aimed to evaluate the significance of C1As among a contemporary cohort of patients with MM in the United States. We used electronic health records from the Flatiron Health database to select patients newly diagnosed with MM from January 2011 to March 2018 who were tested using fluorescence in situ hybridization within 90 days of diagnosis. We characterized patients as having documented C1As or other high-risk chromosomal abnormalities (HRCAs) as defined by the Revised-International Staging System (R-ISS) such as del(17p), t(14;16), and t(4;14). We used Kaplan-Meier methods to compare overall survival (OS) of patients with or without C1As and stratified log-rank tests (with the presence of HRCAs as a stratifying variable). We used Cox proportional hazards regression models to compare OS, adjusting for age, sex, stage, HRCAs, and type of first-line therapy. Of 3578 eligible patients, 844 (24%) had documented C1As. Compared with patients without C1As, patients with C1As were more likely to have higher stage (R-ISS stage III; 18% vs 12%), to have HRCAs (27% vs 14%), and to receive combinations of proteasome inhibitors and immunomodulatory agents (41% vs 34%). Median OS was lower for patients with C1As (46.6 vs 70.1 months; log-rank P &amp;lt; .001). C1As were independently associated with worse OS (adjusted hazard ratio, 1.42; 95% confidence interval, 1.19-2.69; P &amp;lt; .001), as were older age, higher R-ISS stage, HRCAs, and immunoglobulin A isotype. C1As were associated with inferior OS, independent of other HRCAs, despite greater use of novel therapies. Clinical trials testing newer therapies for high-risk MM should incorporate patients with C1As.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001425","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T15:31:21Z","timestamp":1590161481000},"page":"2245-2253","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":45,"title":["Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents"],"prefix":"10.1182","volume":"4","author":[{"given":"Smith","family":"Giri","sequence":"first","affiliation":[{"name":"Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL;"},{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research Center and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7071-6475","authenticated-orcid":false,"given":"Scott F.","family":"Huntington","sequence":"first","affiliation":[{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research Center and"},{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, CT; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"first","affiliation":[{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research Center and"},{"name":"Department of Chronic Disease Epidemiology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"first","affiliation":[{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research Center and"},{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, CT; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3657-778X","authenticated-orcid":false,"given":"Nikolai","family":"Podoltsev","sequence":"first","affiliation":[{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research Center and"},{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, CT; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Gore","sequence":"first","affiliation":[{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research Center and"},{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, CT; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Ma","sequence":"first","affiliation":[{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research Center and"},{"name":"Department of Chronic Disease Epidemiology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary P.","family":"Gross","sequence":"first","affiliation":[{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research Center and"},{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, CT; and"},{"name":"Department of Chronic Disease Epidemiology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8141-9249","authenticated-orcid":false,"given":"Amy J.","family":"Davidoff","sequence":"first","affiliation":[{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research Center and"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Neparidze","sequence":"first","affiliation":[{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research Center and"},{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, CT; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"2020052211304349400_B1","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Myeloma. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed 20 August 2019."},{"issue":"3","key":"2020052211304349400_B2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/leu.2012.282","article-title":"Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project","volume":"27","author":"Avet-Loiseau","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"2020052211304349400_B3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"26","key":"2020052211304349400_B4","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"24","key":"2020052211304349400_B5","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"2A","key":"2020052211304349400_B6","first-page":"953","article-title":"Chromosome 1 abnormalities in multiple myeloma","volume":"26","author":"Marzin","year":"2006","journal-title":"Anticancer Res"},{"issue":"8","key":"2020052211304349400_B7","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2020052211304349400_B8","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","article-title":"Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma","volume":"20","author":"Fonseca","year":"2006","journal-title":"Leukemia"},{"issue":"10","key":"2020052211304349400_B9","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.bbmt.2016.07.007","article-title":"Post-transplant outcomes in high-risk compared with non-high-risk multiple myeloma: A CIBMTR analysis","volume":"22","author":"Scott","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020052211304349400_B10","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2020052211304349400_B11","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3324\/haematol.2014.103853","article-title":"Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies","volume":"99","author":"Caltagirone","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"2020052211304349400_B12","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2020052211304349400_B13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/leu.2011.204","article-title":"A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial","volume":"26","author":"Boyd","year":"2012","journal-title":"Leukemia"},{"issue":"6","key":"2020052211304349400_B14","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ajh.23705","article-title":"Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens","volume":"89","author":"Biran","year":"2014","journal-title":"Am J Hematol"},{"issue":"8","key":"2020052211304349400_B15","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1080\/10428194.2016.1260126","article-title":"Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation","volume":"58","author":"Shah","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2020052211304349400_B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2016.1272684","article-title":"Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group","volume":"58","author":"Grzasko","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2020052211304349400_B17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/leu.2013.225","article-title":"Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients","volume":"28","author":"Hebraud","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"2020052211304349400_B18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020052211304349400_B19","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1111\/1475-6773.12872","article-title":"Development and validation of a high-quality composite real-world mortality endpoint","volume":"53","author":"Curtis","year":"2018","journal-title":"Health Serv Res"},{"issue":"49","key":"2020052211304349400_B20","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/jncimonographs\/lgu020","article-title":"Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in Surveillance, Epidemiology, and End Results (SEER) Registries","volume":"2014","author":"Kish","year":"2014","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"6","key":"2020052211304349400_B21","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood.V97.6.1566","article-title":"Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy","volume":"97","author":"Facon","year":"2001","journal-title":"Blood"},{"issue":"13","key":"2020052211304349400_B22","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood-2014-07-587964","article-title":"Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience","volume":"125","author":"Hebraud","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2020052211304349400_B23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/ejh.12546","article-title":"Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21","volume":"96","author":"Nahi","year":"2016","journal-title":"Eur J Haematol"},{"issue":"12","key":"2020052211304349400_B24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"issue":"4","key":"2020052211304349400_B25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.bbmt.2019.12.726","article-title":"Outcome of multiple myeloma with chromosome 1q gain and 1p deletion after autologous hematopoietic stem cell transplantation: Propensity score matched analysis","volume":"26","author":"Varma","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"2020052211304349400_B26","doi-asserted-by":"crossref","first-page":"Abstract 1805","DOI":"10.1182\/blood-2019-132152","article-title":"Unsupervised Clustering of DNA Copy Number Profiles Identifies a High-Risk Subtype of Hyperdiploid Multiple Myeloma: An Mmrf Commpass Analysis [abstract]","volume":"134","author":"Christofferson","year":"2019","journal-title":"Blood"},{"issue":"30","key":"2020052211304349400_B27","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","article-title":"Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)","volume":"28","author":"Avet-Loiseau","year":"2010","journal-title":"J Clin Oncol"},{"issue":"24","key":"2020052211304349400_B28","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020052211304349400_B29","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/blood-2008-12-193458","article-title":"Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13","volume":"114","author":"Reece","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2020052211304349400_B30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2013.088211","article-title":"Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value","volume":"99","author":"An","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"2020052211304349400_B31","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3109\/10428194.2013.827188","article-title":"Recent improvement in survival of patients with multiple myeloma: variation by ethnicity","volume":"55","author":"Pulte","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2020052211304349400_B32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2141.2012.09124.x","article-title":"Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups","volume":"158","author":"Ailawadhi","year":"2012","journal-title":"Br J Haematol"},{"issue":"8","key":"2020052211304349400_B33","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/cncr.31237","article-title":"Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities","volume":"124","author":"Ailawadhi","year":"2018","journal-title":"Cancer"},{"issue":"4","key":"2020052211304349400_B34","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.bbmt.2014.12.024","article-title":"Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma","volume":"21","author":"Costa","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020052211304349400_B35","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.864.864","article-title":"Racial differences in disease characteristics: Understanding multiple myeloma in Hispanics [abstract]","volume":"130","author":"Jain","year":"2017","journal-title":"Blood"},{"key":"2020052211304349400_B36","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-120282","article-title":"Multiple myeloma in Hispanics is associated with better survival than non-Hispanic African Americans and Whites: Analysis from a large single center minority rich cohort [abstract]","volume":"132","author":"Kaur","year":"2018","journal-title":"Blood"},{"key":"2020052211304349400_B37","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-130639","article-title":"A novel approach to risk stratification in multiple myeloma using ISS stage and FISH [abstract]","volume":"134","author":"Kumar","year":"2019","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/10\/2245\/1731790\/advancesadv2019001425.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/10\/2245\/1731790\/advancesadv2019001425.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T16:52:08Z","timestamp":1666630328000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/10\/2245\/456034\/Chromosome-1-abnormalities-and-survival-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001425","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,22]]}}}